Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 10/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3755286 | 0.92 | AOC3 (0.38) | AOC3ALDH1A1MAPTSMN1; SMN2PIK3CA | |
| SCHEMBL3758928 | 0.90 | ALDH1A1 (0.39) | AOC3ALDH1A1MAPTSMN1; SMN2PIK3CA | |
| SCHEMBL3761443 | 0.89 | ALDH1A1 (0.37) | AOC3ALDH1A1MAPTSMN1; SMN2PIK3CA | |
| SCHEMBL3759346 | 0.88 | AOC3 (0.39) | AOC3SMN1; SMN2PIK3CAPIK3CDPIK3CB | |
| SCHEMBL3751935 | 0.86 | AOC3 (0.40) | AOC3PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3754652 | 0.86 | PIK3CA (0.40) | AOC3ALDH1A1MAPTSMN1; SMN2PIK3CA | |
| SCHEMBL3765101 | 0.85 | PIK3CA (0.38) | ALDH1A1SMN1; SMN2PIK3CAPIK3CDPIK3CB | |
| SCHEMBL3757747 | 0.84 | ALDH1A1 (0.36) | AOC3ALDH1A1MAPTSMN1; SMN2PIK3CA | |
| SCHEMBL3762612 | 0.84 | ALDH1A1 (0.36) | AOC3ALDH1A1MAPTSMN1; SMN2PIK3CA | |
| SCHEMBL3766681 | 0.84 | ALDH1A1 (0.36) | ALDH1A1MAPTSMN1; SMN2PIK3CAPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | AOC3 4160/4885ALDH1A1 3061/4885MAPT 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.